{Reference Type}: Journal Article
{Title}: FDA, CDC, and NIH Co-sponsored Public Workshop Summary-Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea.
{Author}: Hiruy H;Bala S;Byrne JM;Roche KG;Jang SH;Kim P;Nambiar S;Rubin D;Yasinskaya Y;Bachmann LH;Bernstein K;Botgros R;Cammarata S;Chaves RL;Deal CD;Drusano GL;Duffy EM;Eakin AE;Gelone S;Hiltke T;Hook Iii EW;Jerse AE;McNeil CJ;Newman L;O'Brien S;Perry C;Reno HEL;Romaguera RA;Sato J;Unemo M;Wi TEC;Workowski K;O'May GA;Shukla SJ;Farley JJ;
{Journal}: Clin Infect Dis
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 24
{Factor}: 20.999
{DOI}: 10.1093/cid/ciae386
{Abstract}: There is an unmet need for developing drugs for the treatment of gonorrhea, due to rapidly evolving resistance of Neisseria gonorrhoeae against antimicrobial drugs used for empiric therapy, an increase in globally reported multidrug resistant cases, and the limited available therapeutic options. Furthermore, few drugs are under development. Development of antimicrobials is hampered by challenges in clinical trial design, limitations of available diagnostics, changes in and varying standards of care, lack of robust animal models, and clinically relevant pharmacodynamic targets. On April 23, 2021, the U.S. Food and Drug Administration; Centers for Disease Control and Prevention; and National Institute of Allergy and Infectious Diseases, National Institutes of Health co-sponsored a workshop with stakeholders from academia, industry, and regulatory agencies to discuss the challenges and strategies, including potential collaborations and incentives, to facilitate the development of drugs for the treatment of gonorrhea. This article provides a summary of the workshop.